PGXL is an internationally recognized pioneer in the application of molecular diagnostics to pharmacogenetics and is the first laboratory to be CLIA-certified specifically for pharmacogenetics testing. The company was founded in 2005 by Dr. Roland Valdes, Jr., and Dr. Mark W. Linder, researchers who are among the worldwide thought leaders in the science underlying personalized medicine. Our scientists are leading the way in the incorporation of genetic information into the practice of medicine.
Our mission is to enable and advance the use of genetic information in diagnosis and treatment. That requires delivering accurate and timely test results, and to that end we have designed our systems and processes to serve the real-world needs of contract research organizations and practicing physicians. Beyond that, we provide the interpretive guidance required to convert test results into patient-specific therapeutic plans.
PGXL operates as both a commercial and a research laboratory. By straddling these two very different worlds, we’re involved with the development of personalized medicine in a way that other labs are not. We’re conducting the research, developing the assays, and providing the testing and information services that empower personalized medicine. PGXL continually improves both laboratory operations and results-delivery methods so that our customers can be confident they’re getting the information they need to make the best decisions for the improvement of medical treatment. We enable the practice of “precision medicine” for our healthcare clients.
Read about the founders of PGXL here.